Rostra Therapeutics is a Glasgow-based biopharmaceutical company founded in 2022, dedicated to developing innovative treatments for serious infectious diseases. Originating from research at the University of Strathclyde, the company leverages its proprietary second-generation Strathclyde Minor Groove Binders (S-MGBs) platform, which has demonstrated efficacy against a range of pathogens, including fungi, bacteria, viruses, and parasites. With an initial focus on combating invasive fungal infections—a significant global health concern—Rostra aims to address unmet clinical needs through accelerated development programs and strategic collaborations. The company's mission is to restore health and save lives by bringing novel medicines to patients and clinicians worldwide.

​

Approximately 15M people die each year from infectious diseases. This ever-present threat to global health and well-being, and economic prosperity necessitates new and effective therapeutic options to improve the health of patients globally. Rostra Therpeutics has been founded to achieve this goal through its vision to ‘Restore health and save lives through innovative medicines’.

​

Focus on Serious Fungal Disease

​

The initial focus of Rostra Therapeutics will be on developing specific S-MGBs for the treatment of serious invasive fungal infections.  This represents an area of significant unmet clinical need with over 2.55 million directly attributable deaths from invasive fungal diseases each year globally.